HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation

Soo‐Jeong Kim, Kyung Hee Jung, Hong Yan, Mi Kwon Son, Zhenghuan Fang, Ye-Lim Ryu, Hyunseung Lee, Joo Han Lim, Jun–Kyu Suh, Jinhee Kim,

Oncotarget · 2014 · 16 citations · 27 references

DOIFull text

Open access

Concepts

Abstract

// Soo Jung Kim 1,* , Kyung Hee Jung 1,* , Hong Hua Yan 1 , Mi Kwon Son 1 , Zhenghuan Fang 1 , Ye-Lim Ryu 1 , Hyunseung Lee 1 , Joo Han Lim 1 , Jun-Kyu Suh 2 , JinHee Kim 3,4 , Soyoung Lee 3,4 , Sungwoo Hong 3,4 and Soon-Sun Hong 1 1 College of Medicine, Inha University, Sinheung-dong, Jung-gu, Incheon, Republic of Korea 2 National Research Center for Sexual Medicine, College of Medicine, Inha University, Sinheung-dong, Jung-gu, Incheon, Republic of Korea 3 Center for Catalytic Hydrocarbon Functionalizations, Institute for Basic Science (IBS), Republic of Korea 4 Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea * These authors contributed equally to this work Correspondence: Soon-Sun Hong, email: // Sungwoo Hong, email: // Keywords : HS-543, Bcr-Abl, T315I, Chronic Myeloid Leukemia Received : August 04, 2014 Accepted : December 01, 2014 Published : December 02, 2014 Abstract Chronic myeloid leukemia (CML) is characterized by a constitutive activation of Bcr-Abl tyrosine kinase. Bcr-Abl/T315I is the predominant mutation that causes resistance to Imatinib. In the present study, we synthesized a novel Bcr-Abl inhibitor, HS-543, and investigated its effect on cell survival or apoptosis in CML cells bearing Bcr-Abl/T315I (BaF3/T315I) or wild-type Bcr-Abl (BaF3/WT). HS-543 showed anti-proliferative effects in the BaF3/WT cells as well as the BaF3/T315I cells with resistance to Imatinib and strongly inhibited the Bcr-Abl signaling pathway in a dose-dependent manner. Furthermore, it significantly increased the sub G 1 phase associated with early apoptosis, with increased levels of cleaved PARP and cleaved caspase-3, as well as the TUNEL-positive apoptotic cells. In addition, we found that HS-543 induced apoptosis with the loss of mitochondrial membrane potential by decreasing the expression of Mcl-1 and survivin, together with increasing that of Bax. In BaF3/T315I xenograft models, HS-543 significantly delayed tumor growth, unlike Imatinib. Our results demonstrate that HS-543 exhibits the induction of apoptosis and anti-proliferative effect by blocking the Bcr-Abl signaling pathway in the T315I-mutated Bcr-Abl cells with resistance to Imatinib. We suggest that HS-543 may be a novel promising agent to target Bcr-Abl and overcome Imatinib resistance in CML patients.

References

27